Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Cash & Equivalents for 7 consecutive years, with $247.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 124.52% to $247.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was $247.0 million, a 124.52% increase, with the full-year FY2025 number at $247.0 million, up 124.52% from a year prior.
  • Cash & Equivalents was $247.0 million for Q4 2025 at Nurix Therapeutics, up from $78.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $247.0 million in Q4 2025 to a low of $33.6 million in Q1 2023.
  • A 5-year average of $91.3 million and a median of $78.6 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 77.93% in 2022, then soared 134.12% in 2024.
  • Nurix Therapeutics' Cash & Equivalents stood at $80.5 million in 2021, then decreased by 19.91% to $64.5 million in 2022, then dropped by 15.27% to $54.6 million in 2023, then skyrocketed by 101.36% to $110.0 million in 2024, then surged by 124.52% to $247.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Cash & Equivalents are $247.0 million (Q4 2025), $78.4 million (Q3 2025), and $84.3 million (Q2 2025).